The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition

Kawai, Masaaki; Ohtani, Shoichiro; Iwasaki, Motoki; Yamamoto, Seiichiro; Takamatsu, Kiyoshi; Okamura, Hitoshi; Arai, Masami; Nomura, Tsunehisa; Ozaki, Shinji; Shibata, Ken-ichi; Akabane, Ayaka; Motoi, Fuyuhiko; Yamauchi, Chikako; Yamamoto, Yutaka; Iwata, Hiroji; Saji, Shigehira

doi:10.1007/s12282-023-01531-9

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While breast cancer incidence and mortality are on the decline in many countries, Japan is experiencing an upward trend [ 7 , 8 ], necessitating more frequent screening and mammography. Combined with improvements in breast cancer imaging and associated with the detection of even microscopic breast cancers that are non-palpable, the demand for nonsurgical treatment is expected to increase.…”

Section: Introductionmentioning

confidence: 99%

Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan

Kawamoto,

Tsugawa,

Furuya

et al. 2024

Breast Cancer

View full text Add to dashboard Cite

Background Ultrasound-guided percutaneous cryoablation (PCA) for early-stage breast cancer (ESBC) can be performed under local anesthesia in an outpatient clinic. This study continues a pilot stage to examine local control, safety, patient quality of life (QoL), satisfaction and cosmetic outcomes of cryoablation for ESBC. Methods PCA was performed under local anesthesia for patients with primary ESBC, followed by radiation and endocrine therapies. Oncologic outcomes were examined by imaging (mammography, ultrasound, MRI) at baseline and 1, 6, 12, 24, 36, and 60 months post-cryoablation. EQ-VAS, EQ-5D-5L, subjective satisfaction and Moiré topography were used to measure health-related QoL outcomes. Results Eighteen patients, mean aged 59.0 ± 9.0 years, mean tumor size 9.8 ± 2.3 mm, ER + , PR + (17/18), HER2-, Ki67 < 20% (15/18), underwent PCA and were followed for a mean of 44.3 months. No serious adverse events were reported, and no patients had local recurrence or distant metastasis in the 5-year follow-up. Cosmetic outcomes, satisfaction level, and QoL all improved post-cryoablation. Five-year average reduction rates of the cryolesion long, short, and depth diameters, on US, were 61.3%, 42.3%, and 22.8%, respectively, compared to the 86.2% volume reduction rate on MRI. The correlation coefficient between MRI and US measurement criteria was highest for the long diameter. During follow-up, calcification of the treated area was observed in 13/18 cases. Conclusion Cryoablation for ESBC is an effective and safe procedure with excellent cosmetic outcomes and improved QoL. This study contributes to the growing evidence supporting cryoablation as a potential standard treatment for ESBC, given compliance to pre-defined patient selection criteria.

show abstract

Section: Introductionmentioning

confidence: 99%

Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan

Kawamoto,

Tsugawa,

Furuya

et al. 2024

Breast Cancer

View full text Add to dashboard Cite

show abstract

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment

Yamamoto,

Yamauchi,

Toyama

et al. 2024

Breast Cancer

View full text Add to dashboard Cite

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition was published in June 2022. The guidelines were prepared while conforming as much as possible to the “Minds Manual for Guideline Development 2020 ver. 3.0.” edited by the Minds Manual Development Committee of the Japan Council for Quality Health Care in 2021. In addition, a survey of Japanese Breast Cancer Society members on the 2018 edition of the guidelines was conducted from February 19 to March 4, 2021. Based on the responses from over 600 members, original innovations were made to make the guidelines more user-friendly. The 2018 edition of the guidelines was developed to provide support tools for physicians and patients to utilize shared decision-making. The 2022 guidelines consist of two volumes: (1) an “Epidemiology and Diagnosis” section covering “Screening and Diagnosis”, “Radiological diagnosis”, and “Pathological diagnosis”, and (2) a “Treatment” section covering “Surgical therapy”, “Radiation therapy”, and “Systemic therapy”. We believe that this concise summary of the guidelines will be useful to physicians and researchers in Japan and overseas.

show abstract

The role of multiparametric MRI in predicting lymphovascular invasion in breast cancer patients

Wang,

Jing,

Yang

et al. 2024

Future Oncology

View full text Add to dashboard Cite

The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition

Abstract: The Japanese Breast Cancer Society Clinical Practice Guidelines for Epidemiology and Prevention of Breast Cancer, 2022 Edition.

Cited by 4 publications

References 9 publications

Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan

Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment

The role of multiparametric MRI in predicting lymphovascular invasion in breast cancer patients

Contact Info

Product

Resources

About